Aprea Therapeutics AB

ACTIVE

Märsta, Stockholm, Swedenwww.aprea.comPublic1–10 employeesEstablished: 2003-01-01

Part of Aprea Therapeutics

Clinical Trials

9 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2003

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

90.0%

Phase 2

10.0%

Trial Status Distribution

Active, not recruiting

90.0%

Completed

10.0%

Clinical Trials

Trials sponsored by this organization (10)

Study of systemic Azacitidine chemotherapy in combination with or without APR-246 in patients with a type of Myelodysplastic Syndrome

Phase 1

Active, not recruiting

Jul 2019154 participants

study to investigate the safety and clinical activity of APR-246 in combination with dabrafenib in patients with unresectable metastatic melanoma resistant to dabrafenib /trametinib combinatio

Phase 1

Active, not recruiting

Sep 201750 participants

A study of systemic carboplatin/PLD combination chemotherapy with or without APR-246 in patients with Platinum-resistant high grade serous ovarian cancer

Phase 1

Active, not recruiting

May 201725 participants

A study of systemic carboplatin/PLD combination chemotherapy with or without APR-246 in patients with recurrent high grade serous ovarian cancer

Phase 1

Active, not recruiting

Apr 2017400 participants

A study of systemic carboplatin/PLD combination chemotherapy with or without APR-246 in patients with Platinum-resistant high grade serous ovarian cancer

Phase 1

Active, not recruiting

Apr 201725 participants

A study of systemic carboplatin/PLD combination chemotherapy with or without APR-246 in patients with Platinum-resistant high grade serous ovarian cancer

Phase 1

Active, not recruiting

Mar 201750 participants

A study of systemic carboplatin/PLD combination chemotherapy with or without APR-246 in patients with recurrent high grade serous ovarian cancer

Phase 1

Active, not recruiting

Mar 2014400 participants

A study of systemic carboplatin/PLD combination chemotherapy with or without APR-246 in patients with recurrent high grade serous ovarian cancer

Phase 1

Active, not recruiting

Oct 2013400 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations